T cells in myeloma
The current trend to develop immunotherapy strategies for patients with myeloma and other B cell malignancies has stimulated considerable interest in the functional state of the T cell population in these patients. Expanded clones of T cells exist in many patients with myeloma and their presence is...
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2003-03, Vol.21 (1), p.33-42 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 42 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | Hematological oncology |
| container_volume | 21 |
| creator | Raitakari, M. Brown, R. D. Gibson, J. Joshua, D. E. |
| description | The current trend to develop immunotherapy strategies for patients with myeloma and other B cell malignancies has stimulated considerable interest in the functional state of the T cell population in these patients. Expanded clones of T cells exist in many patients with myeloma and their presence is associated with an improved survival. However, isolating T cells with tumour specificity has proven to be a difficult task and clinical immunization trials have so far failed to achieve a significant response. There is now evidence that tumour specific T cells are either tolerized or deleted following antigen presentation and that idiotype‐derived, immunodominant tumour peptides may not exist in all patients. In order to develop more effective immunotherapy strategies for patients with myeloma, further studies are urgently required to identify the most appropriate tumour antigen, the nature of the interactions which take place during antigen presentation, and how to promote the cytotoxicity of autologous T cells. Copyright © 2003 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/hon.704 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73049896</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73049896</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3814-7148269d38f6ed39933bbc111e70163d313155a15dbf3be278bd48883e9629723</originalsourceid><addsrcrecordid>eNp1z01Lw0AQBuBFFFurCP4A6UU9SOruzmY_jlJsq5RWMOJx2SQbjOajZlu0_94tCfbkaQ7z8M68CJ0TPCIY07v3uhoJzA5Qn2ClAoK5OkR9TIUMMAXaQyfOfWDsd1geox6hHIeMkj66iIaJLQo3zKthubVFXZpTdJSZwtmzbg7Q6-QhGs-C-XL6OL6fBwlIwgJBmKRcpSAzblNQCiCOE0KIFZhwSIEACUNDwjTOILb-lThlUkqwilMlKAzQdZu7auqvjXVrXeZu94ypbL1xWgBmSiru4U0Lk6Z2rrGZXjV5aZqtJljv6mtfX_v6Xl52kZu4tOnedX09uOqAcYkpssZUSe72joWcAcXe3bbuOy_s9r97erZctGeDVudubX_-tGk-NRcgQv22mOpo8hI9P8FEh_AL2gl6-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73049896</pqid></control><display><type>article</type><title>T cells in myeloma</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Raitakari, M. ; Brown, R. D. ; Gibson, J. ; Joshua, D. E.</creator><creatorcontrib>Raitakari, M. ; Brown, R. D. ; Gibson, J. ; Joshua, D. E.</creatorcontrib><description>The current trend to develop immunotherapy strategies for patients with myeloma and other B cell malignancies has stimulated considerable interest in the functional state of the T cell population in these patients. Expanded clones of T cells exist in many patients with myeloma and their presence is associated with an improved survival. However, isolating T cells with tumour specificity has proven to be a difficult task and clinical immunization trials have so far failed to achieve a significant response. There is now evidence that tumour specific T cells are either tolerized or deleted following antigen presentation and that idiotype‐derived, immunodominant tumour peptides may not exist in all patients. In order to develop more effective immunotherapy strategies for patients with myeloma, further studies are urgently required to identify the most appropriate tumour antigen, the nature of the interactions which take place during antigen presentation, and how to promote the cytotoxicity of autologous T cells. Copyright © 2003 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.704</identifier><identifier>PMID: 12605421</identifier><identifier>CODEN: HAONDL</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Biological and medical sciences ; CD4-Positive T-Lymphocytes - cytology ; CD8-Positive T-Lymphocytes - cytology ; Humans ; idiotype ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulin Idiotypes ; Immunoglobulinopathies ; Immunopathology ; immunophenotype ; Immunophenotyping ; Medical sciences ; Multiple Myeloma - metabolism ; myeloma ; Peptides - chemistry ; T-cell ; T-Lymphocytes - cytology ; T-Lymphocytes - metabolism ; Time Factors</subject><ispartof>Hematological oncology, 2003-03, Vol.21 (1), p.33-42</ispartof><rights>Copyright © 2003 John Wiley & Sons, Ltd.</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3814-7148269d38f6ed39933bbc111e70163d313155a15dbf3be278bd48883e9629723</citedby><cites>FETCH-LOGICAL-c3814-7148269d38f6ed39933bbc111e70163d313155a15dbf3be278bd48883e9629723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.704$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.704$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14564320$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12605421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raitakari, M.</creatorcontrib><creatorcontrib>Brown, R. D.</creatorcontrib><creatorcontrib>Gibson, J.</creatorcontrib><creatorcontrib>Joshua, D. E.</creatorcontrib><title>T cells in myeloma</title><title>Hematological oncology</title><addtitle>Hematol. Oncol</addtitle><description>The current trend to develop immunotherapy strategies for patients with myeloma and other B cell malignancies has stimulated considerable interest in the functional state of the T cell population in these patients. Expanded clones of T cells exist in many patients with myeloma and their presence is associated with an improved survival. However, isolating T cells with tumour specificity has proven to be a difficult task and clinical immunization trials have so far failed to achieve a significant response. There is now evidence that tumour specific T cells are either tolerized or deleted following antigen presentation and that idiotype‐derived, immunodominant tumour peptides may not exist in all patients. In order to develop more effective immunotherapy strategies for patients with myeloma, further studies are urgently required to identify the most appropriate tumour antigen, the nature of the interactions which take place during antigen presentation, and how to promote the cytotoxicity of autologous T cells. Copyright © 2003 John Wiley & Sons, Ltd.</description><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - cytology</subject><subject>CD8-Positive T-Lymphocytes - cytology</subject><subject>Humans</subject><subject>idiotype</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulin Idiotypes</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>immunophenotype</subject><subject>Immunophenotyping</subject><subject>Medical sciences</subject><subject>Multiple Myeloma - metabolism</subject><subject>myeloma</subject><subject>Peptides - chemistry</subject><subject>T-cell</subject><subject>T-Lymphocytes - cytology</subject><subject>T-Lymphocytes - metabolism</subject><subject>Time Factors</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1z01Lw0AQBuBFFFurCP4A6UU9SOruzmY_jlJsq5RWMOJx2SQbjOajZlu0_94tCfbkaQ7z8M68CJ0TPCIY07v3uhoJzA5Qn2ClAoK5OkR9TIUMMAXaQyfOfWDsd1geox6hHIeMkj66iIaJLQo3zKthubVFXZpTdJSZwtmzbg7Q6-QhGs-C-XL6OL6fBwlIwgJBmKRcpSAzblNQCiCOE0KIFZhwSIEACUNDwjTOILb-lThlUkqwilMlKAzQdZu7auqvjXVrXeZu94ypbL1xWgBmSiru4U0Lk6Z2rrGZXjV5aZqtJljv6mtfX_v6Xl52kZu4tOnedX09uOqAcYkpssZUSe72joWcAcXe3bbuOy_s9r97erZctGeDVudubX_-tGk-NRcgQv22mOpo8hI9P8FEh_AL2gl6-w</recordid><startdate>200303</startdate><enddate>200303</enddate><creator>Raitakari, M.</creator><creator>Brown, R. D.</creator><creator>Gibson, J.</creator><creator>Joshua, D. E.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200303</creationdate><title>T cells in myeloma</title><author>Raitakari, M. ; Brown, R. D. ; Gibson, J. ; Joshua, D. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3814-7148269d38f6ed39933bbc111e70163d313155a15dbf3be278bd48883e9629723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - cytology</topic><topic>CD8-Positive T-Lymphocytes - cytology</topic><topic>Humans</topic><topic>idiotype</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulin Idiotypes</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>immunophenotype</topic><topic>Immunophenotyping</topic><topic>Medical sciences</topic><topic>Multiple Myeloma - metabolism</topic><topic>myeloma</topic><topic>Peptides - chemistry</topic><topic>T-cell</topic><topic>T-Lymphocytes - cytology</topic><topic>T-Lymphocytes - metabolism</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raitakari, M.</creatorcontrib><creatorcontrib>Brown, R. D.</creatorcontrib><creatorcontrib>Gibson, J.</creatorcontrib><creatorcontrib>Joshua, D. E.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raitakari, M.</au><au>Brown, R. D.</au><au>Gibson, J.</au><au>Joshua, D. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>T cells in myeloma</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol. Oncol</addtitle><date>2003-03</date><risdate>2003</risdate><volume>21</volume><issue>1</issue><spage>33</spage><epage>42</epage><pages>33-42</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><coden>HAONDL</coden><abstract>The current trend to develop immunotherapy strategies for patients with myeloma and other B cell malignancies has stimulated considerable interest in the functional state of the T cell population in these patients. Expanded clones of T cells exist in many patients with myeloma and their presence is associated with an improved survival. However, isolating T cells with tumour specificity has proven to be a difficult task and clinical immunization trials have so far failed to achieve a significant response. There is now evidence that tumour specific T cells are either tolerized or deleted following antigen presentation and that idiotype‐derived, immunodominant tumour peptides may not exist in all patients. In order to develop more effective immunotherapy strategies for patients with myeloma, further studies are urgently required to identify the most appropriate tumour antigen, the nature of the interactions which take place during antigen presentation, and how to promote the cytotoxicity of autologous T cells. Copyright © 2003 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>12605421</pmid><doi>10.1002/hon.704</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2003-03, Vol.21 (1), p.33-42 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73049896 |
| source | Wiley-Blackwell Journals; MEDLINE |
| subjects | Biological and medical sciences CD4-Positive T-Lymphocytes - cytology CD8-Positive T-Lymphocytes - cytology Humans idiotype Immunodeficiencies. Immunoglobulinopathies Immunoglobulin Idiotypes Immunoglobulinopathies Immunopathology immunophenotype Immunophenotyping Medical sciences Multiple Myeloma - metabolism myeloma Peptides - chemistry T-cell T-Lymphocytes - cytology T-Lymphocytes - metabolism Time Factors |
| title | T cells in myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A45%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=T%20cells%20in%20myeloma&rft.jtitle=Hematological%20oncology&rft.au=Raitakari,%20M.&rft.date=2003-03&rft.volume=21&rft.issue=1&rft.spage=33&rft.epage=42&rft.pages=33-42&rft.issn=0278-0232&rft.eissn=1099-1069&rft.coden=HAONDL&rft_id=info:doi/10.1002/hon.704&rft_dat=%3Cproquest_cross%3E73049896%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73049896&rft_id=info:pmid/12605421&rfr_iscdi=true |